

Press Release

Cytochroma Inc. Appoints Dr. Alan J. Lewis To Board Of Directors

KINGSTON, Ontario - July 10, 2001 - Cytochroma Inc., today announced the appointment of Alan J. Lewis, Ph.D., President of the Signal Research Division of Celgene, San Diego, California, to its Board of Directors. Dr. Lewis brings to Cytochroma's Board of Directors more than 25 years of experience in drug discovery and development in the biotechnology and pharmaceutical industries.

Dr. Robert Foldes, President & CEO, states "Dr. Lewis provides considerable insight, capabilities and networks to our Company's Board of Directors that will be extremely valuable as we continue to develop the Company, its products and technology platform. I admire his success in creating a fully integrated target and drug discovery company at Signal Pharmaceuticals. We are most pleased to be able to recruit a seasoned executive with such integrity and stature in the biotechnology community."

Dr. Lewis is an internationally recognized biotechnology executive. He has recently served as a Board Member of the Biotechnology Industry Organization (BIO) and Allergan Specialty Therapeutics Inc. (ASTI) and continues to serve as a Board Member of Discovery Partners International. Dr. Lewis joined Signal Pharmaceuticals, Inc. as President in 1994, and he was responsible for managing its acquisition by Celgene Corporation in a stock transaction worth \$275 million at closing. He was also central to the creation of alliances with major international pharmaceutical companies including Akzo Nobel, Ares-Serono, Byk Gulden, Dupont Merck, Novartis, Roche Biosciences and Tanabe Seiyaku.

"My experiences at Signal Pharmaceuticals with a technology platform that focuses on regulating important signal transduction events for therapeutic intervention in cancer, bone metabolism, inflammation and neuroscience, provides a remarkable fit and background with Cytochroma's programs", stated Dr. Lewis. "I am excited with the opportunity to assist Cytochroma, a young, dynamic company which is poised to become the industry leader in the discovery and development of therapeutics based on cytochrome P450 metabolic pathways."

Prior to joining Signal, Dr. Lewis had a distinguished 15 year career with Wyeth-Ayerst where he held senior research positions in its largest research center. This career culminated in his appointment as Vice President of Research, being responsible for numerous programs in

experimental therapeutics and chemistry. His efforts resulted in 20 NCEs being advanced into development, 12 INDs and 4 NDAs (including Efexor, Lodine, Durapro & Oruvail).

Dr. Lewis serves as the editor, member of the editorial boards, or reviewer of many respected journals and he has published over 120 articles and edited seven books.

Cytochroma Inc. is an applied genomics and drug discovery company. It is a world leader in the discovery of cytochrome P450 genes, the identification of the function of the proteins encoded by those genes, and the discovery of highly potent and specific drugs regulating cytochrome P450 enzymes to address unmet medical needs. To date, Cytochroma's drug discovery program has identified modulators of retinoic acid and calcitriol metabolism as drug candidates for the treatment of skin diseases, cancer and bone disorders.

